title: Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
abstract: An increasingly important issue in the management of prostate cancer is the occurrence of biochemical failure (ie, increasing serum prostate-specific antigen [PSA] levels) in patients with clinically localized prostate cancer who initially underwent definitive treatments with curative intent (prostatectomy and/or radiation therapy). This pilot trial evaluated chemotherapy followed by hormone therapy for a defined period in patients with biochemical (and possibly clinical) recurrence after initial local therapies for localized/locally advanced prostate cancer. Patients who developed increasing PSA > 4 ng/mL after initial prostatectomy and/or radiation therapy received docetaxel, 70 mg/m(2) every 3 weeks for up to 6 courses, followed by 4 months of total androgen suppression (using a luteinizing hormone-releasing hormone agonist plus bicalutamide, 50 mg/d) and 8 months of peripheral androgen blockade (using finasteride, 5 mg/d, plus bicalutamide, 50 mg/d). Twenty-seven patients have enrolled to date, 23 of whom received four or six cycles of docetaxel before hormonal therapies. Seventeen (74%) of 23 patients who completed four to six cycles of chemotherapy had a > or =40% decrease in PSA, and 16 (89%) of 18 patients who completed 4 months of total androgen suppression achieved PSA values of < or =0.1. The most common hematologic toxicity was grade (3/4) neutropenia; grade 3 nonhematologic toxicities were rare, and no grade 4 nonhematologic toxicities were reported. Thus, the preliminary results suggest that docetaxel before hormonal therapy includes a PSA response in many prostate cancer patients with biochemical failure after definitive local therapies.
authors.affiliation: Greenebaum Cancer Center, University of Maryland School of Medicine, and the Baltimore Veterans Affairs Medical Center, Department of Veterans Affairs, Baltimore, MD 21201, USA.
authors.forename: A
authors.initials: A
authors.lastname: Hussain
authors.forename: N
authors.initials: N
authors.lastname: Dawson
authors.forename: P
authors.initials: P
authors.lastname: Amin
authors.forename: M
authors.initials: M
authors.lastname: Naslund
authors.forename: C
authors.initials: C
authors.lastname: Engstrom
authors.forename: T
authors.initials: T
authors.lastname: Chen
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000813:Anilides / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D000077143:Docetaxel; D018120:Finasteride / Q000627:therapeutic use; D017273:Goserelin / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009570:Nitriles; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D010865:Pilot Projects; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D016879:Salvage Therapy; D043823:Taxoids; D014105:Tosyl Compounds
chemical_list: D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D000972:Antineoplastic Agents, Phytogenic; D009570:Nitriles; D043823:Taxoids; D014105:Tosyl Compounds; D017273:Goserelin; D000077143:Docetaxel; D018120:Finasteride; C053541:bicalutamide; D017430:Prostate-Specific Antigen; D016729:Leuprolide; D017239:Paclitaxel